JP2005040137A - Ｊｎｋを標的化することによりプログラム細胞死またはアポトーシスをブロックする新規な因子の同定 - Google Patents

Info

Publication number

JP2005040137A

JP2005040137A JP2004218009A JP2004218009A JP2005040137A JP 2005040137 A JP2005040137 A JP 2005040137A JP 2004218009 A JP2004218009 A JP 2004218009A JP 2004218009 A JP2004218009 A JP 2004218009A JP 2005040137 A JP2005040137 A JP 2005040137A

Authority

JP

Japan

Prior art keywords

gadd45β

jnk

factor

cells

jnkk2

Prior art date

2003-07-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 238000003782 apoptosis assay Methods 0.000 title claims abstract description 48
• 230000005522 programmed cell death Effects 0.000 title claims abstract description 46
• 230000006907 apoptotic process Effects 0.000 title claims description 157
• 230000008685 targeting Effects 0.000 title description 14
• 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims abstract description 422
• 238000000034 method Methods 0.000 claims abstract description 196
• 230000037361 pathway Effects 0.000 claims abstract description 181
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 128
• 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 49
• 239000003795 chemical substances by application Substances 0.000 claims abstract description 32
• 239000000203 mixture Substances 0.000 claims abstract description 27
• 230000001105 regulatory effect Effects 0.000 claims abstract description 23
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 15
• 230000002452 interceptive effect Effects 0.000 claims abstract description 12
• 108010057466 NF-kappa B Proteins 0.000 claims description 264
• 102000003945 NF-kappa B Human genes 0.000 claims description 264
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 170
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 170
• 230000004913 activation Effects 0.000 claims description 134
• 230000000694 effects Effects 0.000 claims description 132
• 108090000623 proteins and genes Proteins 0.000 claims description 119
• 101000624594 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 7 Proteins 0.000 claims description 111
• 102100023332 Dual specificity mitogen-activated protein kinase kinase 7 Human genes 0.000 claims description 109
• 206010028980 Neoplasm Diseases 0.000 claims description 108
• 238000009739 binding Methods 0.000 claims description 101
• 230000027455 binding Effects 0.000 claims description 100
• 201000011510 cancer Diseases 0.000 claims description 87
• 102000004169 proteins and genes Human genes 0.000 claims description 83
• 230000014509 gene expression Effects 0.000 claims description 70
• 230000005764 inhibitory process Effects 0.000 claims description 68
• 230000011664 signaling Effects 0.000 claims description 60
• 239000003112 inhibitor Substances 0.000 claims description 58
• 238000000338 in vitro Methods 0.000 claims description 48
• 101150033270 Gadd45a gene Proteins 0.000 claims description 44
• 230000006870 function Effects 0.000 claims description 40
• 230000000692 anti-sense effect Effects 0.000 claims description 39
• 239000002299 complementary DNA Substances 0.000 claims description 39
• 108700007032 GADD45 Proteins 0.000 claims description 32
• 102000054184 GADD45 Human genes 0.000 claims description 32
• 239000012634 fragment Substances 0.000 claims description 32
• 238000012216 screening Methods 0.000 claims description 31
• 230000002401 inhibitory effect Effects 0.000 claims description 27
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
• 230000001965 increasing effect Effects 0.000 claims description 24
• 241001465754 Metazoa Species 0.000 claims description 23
• 230000003828 downregulation Effects 0.000 claims description 23
• 238000001727 in vivo Methods 0.000 claims description 22
• 230000000903 blocking effect Effects 0.000 claims description 21
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 19
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 19
• 229960000975 daunorubicin Drugs 0.000 claims description 19
• 230000003827 upregulation Effects 0.000 claims description 16
• 239000002773 nucleotide Substances 0.000 claims description 15
• 125000003729 nucleotide group Chemical group 0.000 claims description 15
• 108091034117 Oligonucleotide Proteins 0.000 claims description 14
• 150000001413 amino acids Chemical class 0.000 claims description 14
• 230000001629 suppression Effects 0.000 claims description 13
• 102000053642 Catalytic RNA Human genes 0.000 claims description 12
• 108090000994 Catalytic RNA Proteins 0.000 claims description 12
• 108091092562 ribozyme Proteins 0.000 claims description 12
• 239000000074 antisense oligonucleotide Substances 0.000 claims description 11
• 238000012230 antisense oligonucleotides Methods 0.000 claims description 11
• 231100000024 genotoxic Toxicity 0.000 claims description 11
• 230000001738 genotoxic effect Effects 0.000 claims description 11
• 150000003384 small molecules Chemical group 0.000 claims description 11
• 108010021466 Mutant Proteins Proteins 0.000 claims description 10
• 102000008300 Mutant Proteins Human genes 0.000 claims description 10
• 239000000816 peptidomimetic Substances 0.000 claims description 10
• 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 8
• 210000000987 immune system Anatomy 0.000 claims description 8
• 230000001052 transient effect Effects 0.000 claims description 8
• 230000003412 degenerative effect Effects 0.000 claims description 7
• 229930014626 natural product Natural products 0.000 claims description 7
• 239000000126 substance Substances 0.000 claims description 7
• 108020004459 Small interfering RNA Proteins 0.000 claims description 6
• 230000002708 enhancing effect Effects 0.000 claims description 6
• 230000003278 mimic effect Effects 0.000 claims description 5
• 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 4
• 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 4
• 150000001720 carbohydrates Chemical class 0.000 claims description 4
• 150000002632 lipids Chemical class 0.000 claims description 4
• 230000003213 activating effect Effects 0.000 claims description 3
• 239000004055 small Interfering RNA Substances 0.000 claims description 3
• 229940126062 Compound A Drugs 0.000 claims description 2
• 230000002633 protecting effect Effects 0.000 claims description 2
• 210000004027 cell Anatomy 0.000 description 379
• 238000011282 treatment Methods 0.000 description 78
• 102000004196 processed proteins & peptides Human genes 0.000 description 57
• YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 50
• 230000006698 induction Effects 0.000 description 49
• 230000002147 killing effect Effects 0.000 description 46
• 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 42
• 239000013612 plasmid Substances 0.000 description 37
• 101710123496 Spindolin Proteins 0.000 description 35
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 34
• 238000003556 assay Methods 0.000 description 34
• 230000007246 mechanism Effects 0.000 description 34
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 34
• 150000001875 compounds Chemical class 0.000 description 33
• 241000699666 Mus <mouse, genus> Species 0.000 description 32
• 108091000080 Phosphotransferase Proteins 0.000 description 32
• 102000020233 phosphotransferase Human genes 0.000 description 32
• 230000004083 survival effect Effects 0.000 description 31
• 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 29
• 239000000284 extract Substances 0.000 description 29
• 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 28
• 108020004414 DNA Proteins 0.000 description 27
• 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 27
• 101150064015 FAS gene Proteins 0.000 description 27
• 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 27
• 150000007523 nucleic acids Chemical class 0.000 description 27
• 102000011727 Caspases Human genes 0.000 description 26
• 108010076667 Caspases Proteins 0.000 description 26
• 229920001184 polypeptide Polymers 0.000 description 26
• 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 25
• 230000001419 dependent effect Effects 0.000 description 25
• 238000001262 western blot Methods 0.000 description 25
• 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 24
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 23
• 210000002950 fibroblast Anatomy 0.000 description 23
• 230000003993 interaction Effects 0.000 description 23
• 230000001681 protective effect Effects 0.000 description 23
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 22
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 22
• 208000005623 Carcinogenesis Diseases 0.000 description 21
• 102000004127 Cytokines Human genes 0.000 description 21
• 108090000695 Cytokines Proteins 0.000 description 21
• 108010049207 Death Domain Receptors Proteins 0.000 description 21
• 102000009058 Death Domain Receptors Human genes 0.000 description 21
• 230000033228 biological regulation Effects 0.000 description 21
• 230000036952 cancer formation Effects 0.000 description 21
• 231100000504 carcinogenesis Toxicity 0.000 description 21
• 102000039446 nucleic acids Human genes 0.000 description 21
• 108020004707 nucleic acids Proteins 0.000 description 21
• 230000001225 therapeutic effect Effects 0.000 description 21
• 108010070675 Glutathione transferase Proteins 0.000 description 20
• 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 20
• 102000043136 MAP kinase family Human genes 0.000 description 20
• 108091054455 MAP kinase family Proteins 0.000 description 20
• 238000000021 kinase assay Methods 0.000 description 20
• 239000002246 antineoplastic agent Substances 0.000 description 19
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
• 239000003814 drug Substances 0.000 description 18
• 238000002474 experimental method Methods 0.000 description 18
• 210000004287 null lymphocyte Anatomy 0.000 description 18
• 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 17
• 108700012411 TNFSF10 Proteins 0.000 description 17
• 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 17
• 229940024606 amino acid Drugs 0.000 description 17
• 230000002424 anti-apoptotic effect Effects 0.000 description 17
• 229940127089 cytotoxic agent Drugs 0.000 description 17
• 239000013598 vector Substances 0.000 description 17
• 102100033060 Mitogen-activated protein kinase kinase kinase 4 Human genes 0.000 description 16
• 201000010099 disease Diseases 0.000 description 16
• 238000002337 electrophoretic mobility shift assay Methods 0.000 description 16
• 239000000523 sample Substances 0.000 description 16
• 210000004881 tumor cell Anatomy 0.000 description 16
• 208000026310 Breast neoplasm Diseases 0.000 description 15
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
• 239000000872 buffer Substances 0.000 description 15
• 230000003013 cytotoxicity Effects 0.000 description 15
• 231100000135 cytotoxicity Toxicity 0.000 description 15
• 206010006187 Breast cancer Diseases 0.000 description 14
• OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 14
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 14
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 14
• 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 14
• 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 14
• 101710176384 Peptide 1 Proteins 0.000 description 14
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
• 102000040945 Transcription factor Human genes 0.000 description 14
• 108091023040 Transcription factor Proteins 0.000 description 14
• 230000030833 cell death Effects 0.000 description 14
• 230000004568 DNA-binding Effects 0.000 description 13
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 13
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 13
• 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 13
• 108010075647 MAP Kinase Kinase Kinase 4 Proteins 0.000 description 13
• 108030005453 Mitogen-activated protein kinase kinase kinases Proteins 0.000 description 13
• 239000012190 activator Substances 0.000 description 13
• 229940079593 drug Drugs 0.000 description 13
• 230000014616 translation Effects 0.000 description 13
• 230000005735 apoptotic response Effects 0.000 description 12
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 12
• 229960004316 cisplatin Drugs 0.000 description 12
• 230000001404 mediated effect Effects 0.000 description 12
• 230000026731 phosphorylation Effects 0.000 description 12
• 238000006366 phosphorylation reaction Methods 0.000 description 12
• 238000012360 testing method Methods 0.000 description 12
• 238000013518 transcription Methods 0.000 description 12
• 230000035897 transcription Effects 0.000 description 12
• 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 11
• 102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 11
• 108700020796 Oncogene Proteins 0.000 description 11
• 230000034994 death Effects 0.000 description 11
• 230000002950 deficient Effects 0.000 description 11
• 239000005090 green fluorescent protein Substances 0.000 description 11
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 11
• 238000013519 translation Methods 0.000 description 11
• 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 10
• 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 10
• 210000003719 b-lymphocyte Anatomy 0.000 description 10
• 239000011324 bead Substances 0.000 description 10
• 239000013592 cell lysate Substances 0.000 description 10
• 238000006243 chemical reaction Methods 0.000 description 10
• 108010038795 estrogen receptors Proteins 0.000 description 10
• 230000035772 mutation Effects 0.000 description 10
• 230000004224 protection Effects 0.000 description 10
• 238000001890 transfection Methods 0.000 description 10
• 238000011144 upstream manufacturing Methods 0.000 description 10
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
• 239000007995 HEPES buffer Substances 0.000 description 9
• 208000017604 Hodgkin disease Diseases 0.000 description 9
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 9
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 9
• -1 adhesion molecules Proteins 0.000 description 9
• 238000004458 analytical method Methods 0.000 description 9
• 230000001640 apoptogenic effect Effects 0.000 description 9
• 210000004899 c-terminal region Anatomy 0.000 description 9
• 238000002512 chemotherapy Methods 0.000 description 9
• 230000001684 chronic effect Effects 0.000 description 9
• 239000000539 dimer Substances 0.000 description 9
• 239000012636 effector Substances 0.000 description 9
• 238000000684 flow cytometry Methods 0.000 description 9
• 230000002779 inactivation Effects 0.000 description 9
• 230000002438 mitochondrial effect Effects 0.000 description 9
• 230000000861 pro-apoptotic effect Effects 0.000 description 9
• 239000000758 substrate Substances 0.000 description 9
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
• DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 8
• 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 8
• 102000011855 MAP Kinase Kinase Kinase 1 Human genes 0.000 description 8
• 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 8
• 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 8
• 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 8
• 108091028043 Nucleic acid sequence Proteins 0.000 description 8
• 230000002596 correlated effect Effects 0.000 description 8
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 102000015694 estrogen receptors Human genes 0.000 description 8
• 230000004927 fusion Effects 0.000 description 8
• 238000001114 immunoprecipitation Methods 0.000 description 8
• 238000009169 immunotherapy Methods 0.000 description 8
• 238000011534 incubation Methods 0.000 description 8
• 230000001939 inductive effect Effects 0.000 description 8
• 239000003446 ligand Substances 0.000 description 8
• 238000011275 oncology therapy Methods 0.000 description 8
• 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 230000000770 proinflammatory effect Effects 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 230000035945 sensitivity Effects 0.000 description 8
• 238000010186 staining Methods 0.000 description 8
• 108091026890 Coding region Proteins 0.000 description 7
• 238000002965 ELISA Methods 0.000 description 7
• 241000699670 Mus sp. Species 0.000 description 7
• 239000004098 Tetracycline Substances 0.000 description 7
• 108700009124 Transcription Initiation Site Proteins 0.000 description 7
• 102100023132 Transcription factor Jun Human genes 0.000 description 7
• 230000005775 apoptotic pathway Effects 0.000 description 7
• 230000000875 corresponding effect Effects 0.000 description 7
• 230000001120 cytoprotective effect Effects 0.000 description 7
• 231100000433 cytotoxic Toxicity 0.000 description 7
• 230000001472 cytotoxic effect Effects 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 7
• PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 7
• 210000004698 lymphocyte Anatomy 0.000 description 7
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 7
• 230000002018 overexpression Effects 0.000 description 7
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 7
• 230000000144 pharmacologic effect Effects 0.000 description 7
• 102000040430 polynucleotide Human genes 0.000 description 7
• 108091033319 polynucleotide Proteins 0.000 description 7
• 239000002157 polynucleotide Substances 0.000 description 7
• 230000003389 potentiating effect Effects 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 102000005962 receptors Human genes 0.000 description 7
• 108020003175 receptors Proteins 0.000 description 7
• 239000011780 sodium chloride Substances 0.000 description 7
• 230000002459 sustained effect Effects 0.000 description 7
• 229930101283 tetracycline Natural products 0.000 description 7
• 229960002180 tetracycline Drugs 0.000 description 7
• 235000019364 tetracycline Nutrition 0.000 description 7
• 150000003522 tetracyclines Chemical class 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• 230000001988 toxicity Effects 0.000 description 7
• 231100000419 toxicity Toxicity 0.000 description 7
• 102000004091 Caspase-8 Human genes 0.000 description 6
• 108090000538 Caspase-8 Proteins 0.000 description 6
• 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 6
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 6
• 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 6
• 208000034578 Multiple myelomas Diseases 0.000 description 6
• 238000000636 Northern blotting Methods 0.000 description 6
• 206010035226 Plasma cell myeloma Diseases 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 230000001580 bacterial effect Effects 0.000 description 6
• 230000003197 catalytic effect Effects 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 239000002158 endotoxin Substances 0.000 description 6
• 239000013613 expression plasmid Substances 0.000 description 6
• 238000001415 gene therapy Methods 0.000 description 6
• 230000004968 inflammatory condition Effects 0.000 description 6
• 229920006008 lipopolysaccharide Polymers 0.000 description 6
• 238000003752 polymerase chain reaction Methods 0.000 description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• 102100022291 C-Jun-amino-terminal kinase-interacting protein 1 Human genes 0.000 description 5
• 101001046660 Homo sapiens C-Jun-amino-terminal kinase-interacting protein 1 Proteins 0.000 description 5
• 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 5
• 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 5
• 102000043276 Oncogene Human genes 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• 229920004890 Triton X-100 Polymers 0.000 description 5
• 239000013504 Triton X-100 Substances 0.000 description 5
• 230000003321 amplification Effects 0.000 description 5
• 238000011319 anticancer therapy Methods 0.000 description 5
• 230000009286 beneficial effect Effects 0.000 description 5
• 238000000749 co-immunoprecipitation Methods 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 5
• 230000008030 elimination Effects 0.000 description 5
• 238000003379 elimination reaction Methods 0.000 description 5
• 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 5
• 108020001507 fusion proteins Proteins 0.000 description 5
• 102000037865 fusion proteins Human genes 0.000 description 5
• 239000003862 glucocorticoid Substances 0.000 description 5
• 230000001506 immunosuppresive effect Effects 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 239000006166 lysate Substances 0.000 description 5
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 5
• 108020004999 messenger RNA Proteins 0.000 description 5
• 238000003199 nucleic acid amplification method Methods 0.000 description 5
• 230000035790 physiological processes and functions Effects 0.000 description 5
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 5
• 238000012545 processing Methods 0.000 description 5
• 238000012163 sequencing technique Methods 0.000 description 5
• 229940037128 systemic glucocorticoids Drugs 0.000 description 5
• 230000002103 transcriptional effect Effects 0.000 description 5
• 230000009466 transformation Effects 0.000 description 5
• BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 description 4
• 208000023275 Autoimmune disease Diseases 0.000 description 4
• 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 4
• 108020004635 Complementary DNA Proteins 0.000 description 4
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
• 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 4
• 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 4
• 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• 101710155270 Glycerate 2-kinase Proteins 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 4
• 101000893424 Homo sapiens Glucokinase regulatory protein Proteins 0.000 description 4
• 101001018145 Homo sapiens Mitogen-activated protein kinase kinase kinase 3 Proteins 0.000 description 4
• 101001059982 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 5 Proteins 0.000 description 4
• 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 4
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 4
• 229940124647 MEK inhibitor Drugs 0.000 description 4
• 102100033059 Mitogen-activated protein kinase kinase kinase 3 Human genes 0.000 description 4
• 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 description 4
• 101710144533 Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 4
• 102100028195 Mitogen-activated protein kinase kinase kinase kinase 5 Human genes 0.000 description 4
• 108700026226 TATA Box Proteins 0.000 description 4
• 102000004398 TNF receptor-associated factor 1 Human genes 0.000 description 4
• 108090000920 TNF receptor-associated factor 1 Proteins 0.000 description 4
• 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 4
• 238000011394 anticancer treatment Methods 0.000 description 4
• 239000000427 antigen Substances 0.000 description 4
• 108091007433 antigens Proteins 0.000 description 4
• 102000036639 antigens Human genes 0.000 description 4
• 230000001363 autoimmune Effects 0.000 description 4
• 101150055766 cat gene Proteins 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 230000007123 defense Effects 0.000 description 4
• 238000013461 design Methods 0.000 description 4
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 4
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 230000028993 immune response Effects 0.000 description 4
• 230000037451 immune surveillance Effects 0.000 description 4
• 230000028709 inflammatory response Effects 0.000 description 4
• 230000036210 malignancy Effects 0.000 description 4
• 210000003470 mitochondria Anatomy 0.000 description 4
• 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 238000002823 phage display Methods 0.000 description 4
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• BGKHCLZFGPIKKU-LDDQNKHRSA-N prostaglandin A1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O BGKHCLZFGPIKKU-LDDQNKHRSA-N 0.000 description 4
• 230000009979 protective mechanism Effects 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 230000005855 radiation Effects 0.000 description 4
• 238000001959 radiotherapy Methods 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 238000007423 screening assay Methods 0.000 description 4
• 239000000600 sorbitol Substances 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 238000003146 transient transfection Methods 0.000 description 4
• 238000010396 two-hybrid screening Methods 0.000 description 4
• 238000005199 ultracentrifugation Methods 0.000 description 4
• 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 3
• 108020005544 Antisense RNA Proteins 0.000 description 3
• 208000003950 B-cell lymphoma Diseases 0.000 description 3
• 102000051485 Bcl-2 family Human genes 0.000 description 3
• 108700038897 Bcl-2 family Proteins 0.000 description 3
• 102100026189 Beta-galactosidase Human genes 0.000 description 3
• 102000004046 Caspase-2 Human genes 0.000 description 3
• 108090000552 Caspase-2 Proteins 0.000 description 3
• 102000047934 Caspase-3/7 Human genes 0.000 description 3
• 108700037887 Caspase-3/7 Proteins 0.000 description 3
• 102100026550 Caspase-9 Human genes 0.000 description 3
• 108090000566 Caspase-9 Proteins 0.000 description 3
• 238000007400 DNA extraction Methods 0.000 description 3
• 101710146518 Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 3
• 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 102100026693 FAS-associated death domain protein Human genes 0.000 description 3
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
• 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 3
• 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 3
• 101001018147 Homo sapiens Mitogen-activated protein kinase kinase kinase 4 Proteins 0.000 description 3
• 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 3
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
• 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 3
• 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 3
• 108090000144 Human Proteins Proteins 0.000 description 3
• 102000003839 Human Proteins Human genes 0.000 description 3
• 102100025180 Mitogen-activated protein kinase kinase kinase 12 Human genes 0.000 description 3
• 108090000143 Mouse Proteins Proteins 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• 102000001253 Protein Kinase Human genes 0.000 description 3
• 210000001744 T-lymphocyte Anatomy 0.000 description 3
• 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 3
• 102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 3
• 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 3
• 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 3
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 230000001270 agonistic effect Effects 0.000 description 3
• 230000009925 apoptotic mechanism Effects 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 230000008827 biological function Effects 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 3
• 239000001506 calcium phosphate Substances 0.000 description 3
• 229910000389 calcium phosphate Inorganic materials 0.000 description 3
• 235000011010 calcium phosphates Nutrition 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 230000005754 cellular signaling Effects 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• 230000007812 deficiency Effects 0.000 description 3
• 230000005014 ectopic expression Effects 0.000 description 3
• 230000002900 effect on cell Effects 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 239000000833 heterodimer Substances 0.000 description 3
• 239000000710 homodimer Substances 0.000 description 3
• 102000057989 human MAP3K5 Human genes 0.000 description 3
• 102000057041 human TNF Human genes 0.000 description 3
• 239000012742 immunoprecipitation (IP) buffer Substances 0.000 description 3
• 238000000099 in vitro assay Methods 0.000 description 3
• 239000003999 initiator Substances 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 239000012139 lysis buffer Substances 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 238000010606 normalization Methods 0.000 description 3
• KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 3
• 239000008194 pharmaceutical composition Substances 0.000 description 3
• SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 description 3
• 230000010399 physical interaction Effects 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 238000011533 pre-incubation Methods 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 108091008146 restriction endonucleases Proteins 0.000 description 3
• 230000000717 retained effect Effects 0.000 description 3
• 239000000243 solution Substances 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
• 230000005740 tumor formation Effects 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
• 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
• 108010085238 Actins Proteins 0.000 description 2
• 229930024421 Adenine Natural products 0.000 description 2
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
• 101100080292 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pltp gene Proteins 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• 102100036465 Autoimmune regulator Human genes 0.000 description 2
• 108091007065 BIRCs Proteins 0.000 description 2
• 108700020463 BRCA1 Proteins 0.000 description 2
• 101150072950 BRCA1 gene Proteins 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 102100021677 Baculoviral IAP repeat-containing protein 2 Human genes 0.000 description 2
• 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 description 2
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
• 102100022287 C-Jun-amino-terminal kinase-interacting protein 2 Human genes 0.000 description 2
• 108090000397 Caspase 3 Proteins 0.000 description 2
• 102000004018 Caspase 6 Human genes 0.000 description 2
• 108090000425 Caspase 6 Proteins 0.000 description 2
• 102100029855 Caspase-3 Human genes 0.000 description 2
• 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
• 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 230000005778 DNA damage Effects 0.000 description 2
• 231100000277 DNA damage Toxicity 0.000 description 2
• 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 108700006830 Drosophila Antp Proteins 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 102100038595 Estrogen receptor Human genes 0.000 description 2
• 108010039471 Fas Ligand Protein Proteins 0.000 description 2
• 101150112014 Gapdh gene Proteins 0.000 description 2
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
• 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 description 2
• 101001046656 Homo sapiens C-Jun-amino-terminal kinase-interacting protein 2 Proteins 0.000 description 2
• 101001005602 Homo sapiens Mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 description 2
• 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 239000012825 JNK inhibitor Substances 0.000 description 2
• 229940118135 JNK inhibitor Drugs 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
• 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
• 102000010049 MAP kinase kinase kinase kinase activity proteins Human genes 0.000 description 2
• 108040005742 MAP kinase kinase kinase kinase activity proteins Proteins 0.000 description 2
• 231100000070 MTS assay Toxicity 0.000 description 2
• 238000000719 MTS assay Methods 0.000 description 2
• 102100038243 Mitogen-activated protein kinase kinase kinase 10 Human genes 0.000 description 2
• 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 101100077749 Mus musculus Map2k4 gene Proteins 0.000 description 2
• 101100236412 Mus musculus Map3k4 gene Proteins 0.000 description 2
• 101100190814 Mus musculus Pltp gene Proteins 0.000 description 2
• 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 2
• 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 2
• 102000055056 N-Myc Proto-Oncogene Human genes 0.000 description 2
• BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 2
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
• MYHXHCUNDDAEOZ-UHFFFAOYSA-N Prostaglandin A&2% Natural products CCCCCC(O)C=CC1C=CC(=O)C1CC=CCCCC(O)=O MYHXHCUNDDAEOZ-UHFFFAOYSA-N 0.000 description 2
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
• 101150033538 Rala gene Proteins 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 108700008625 Reporter Genes Proteins 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 2
• 108700019146 Transgenes Proteins 0.000 description 2
• 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 2
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 229960001138 acetylsalicylic acid Drugs 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 229960000643 adenine Drugs 0.000 description 2
• 230000001464 adherent effect Effects 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 238000001261 affinity purification Methods 0.000 description 2
• 101150045355 akt1 gene Proteins 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 230000000259 anti-tumor effect Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 238000003491 array Methods 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 238000010256 biochemical assay Methods 0.000 description 2
• 230000022131 cell cycle Effects 0.000 description 2
• 230000022534 cell killing Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 230000010307 cell transformation Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 230000009137 competitive binding Effects 0.000 description 2
• 238000004624 confocal microscopy Methods 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 230000008260 defense mechanism Effects 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 229960005420 etoposide Drugs 0.000 description 2
• 230000001605 fetal effect Effects 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 229930182470 glycoside Natural products 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 238000013537 high throughput screening Methods 0.000 description 2
• 102000053447 human MAP2K7 Human genes 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000003308 immunostimulating effect Effects 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 230000000415 inactivating effect Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 239000007928 intraperitoneal injection Substances 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 239000006193 liquid solution Substances 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 229960001924 melphalan Drugs 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 238000000386 microscopy Methods 0.000 description 2
• 230000027829 mitochondrial depolarization Effects 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 239000002991 molded plastic Substances 0.000 description 2
• 230000004001 molecular interaction Effects 0.000 description 2
• 239000003068 molecular probe Substances 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 230000005937 nuclear translocation Effects 0.000 description 2
• 238000001668 nucleic acid synthesis Methods 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 229940069510 parthenolide Drugs 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
• 231100000683 possible toxicity Toxicity 0.000 description 2
• 230000001686 pro-survival effect Effects 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 238000012342 propidium iodide staining Methods 0.000 description 2
• 238000000159 protein binding assay Methods 0.000 description 2
• 238000001243 protein synthesis Methods 0.000 description 2
• 230000004850 protein–protein interaction Effects 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 108700015048 receptor decoy activity proteins Proteins 0.000 description 2
• 230000025915 regulation of apoptotic process Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000004043 responsiveness Effects 0.000 description 2
• 210000001995 reticulocyte Anatomy 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 230000030968 tissue homeostasis Effects 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 238000011830 transgenic mouse model Methods 0.000 description 2
• 230000005760 tumorsuppression Effects 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 210000002845 virion Anatomy 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 1
• HJEZFVLKJYFNQW-PRFXOSGESA-N (13S)-13-dihydrodaunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)[C@H](C)O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 HJEZFVLKJYFNQW-PRFXOSGESA-N 0.000 description 1
• NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 description 1
• GKWWIZOKXSWGTQ-UHFFFAOYSA-N 3-(trifluoromethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(C(F)(F)F)=CC2=C1 GKWWIZOKXSWGTQ-UHFFFAOYSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
• YKJYKKNCCRKFSL-UHFFFAOYSA-N Anisomycin Natural products C1=CC(OC)=CC=C1CC1C(OC(C)=O)C(O)CN1 YKJYKKNCCRKFSL-UHFFFAOYSA-N 0.000 description 1
• 230000020955 B cell costimulation Effects 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 102100025903 C-Jun-amino-terminal kinase-interacting protein 3 Human genes 0.000 description 1
• 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 description 1
• 101150012716 CDK1 gene Proteins 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 108090000567 Caspase 7 Proteins 0.000 description 1
• 229940123169 Caspase inhibitor Drugs 0.000 description 1
• 102100038902 Caspase-7 Human genes 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 108091062157 Cis-regulatory element Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 101710094648 Coat protein Proteins 0.000 description 1
• 241000195493 Cryptophyta Species 0.000 description 1
• 108050006400 Cyclin Proteins 0.000 description 1
• 102100033233 Cyclin-dependent kinase inhibitor 1B Human genes 0.000 description 1
• 238000012287 DNA Binding Assay Methods 0.000 description 1
• 239000012624 DNA alkylating agent Substances 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• HJEZFVLKJYFNQW-UHFFFAOYSA-N Daunorubicinol Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)O)CC1OC1CC(N)C(O)C(C)O1 HJEZFVLKJYFNQW-UHFFFAOYSA-N 0.000 description 1
• OWCHPBVMSHIYCQ-UHFFFAOYSA-N Dihydro-dauno-mycinon Natural products C1C(O)(C(C)O)CC(O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O OWCHPBVMSHIYCQ-UHFFFAOYSA-N 0.000 description 1
• 101150011762 Dredd gene Proteins 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000672609 Escherichia coli BL21 Species 0.000 description 1
• 101710134671 Executioner caspase Proteins 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 230000020172 G2/M transition checkpoint Effects 0.000 description 1
• 102100039556 Galectin-4 Human genes 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 101150009006 HIS3 gene Proteins 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
• 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
• 108050003783 Histidinol-phosphate aminotransferase Proteins 0.000 description 1
• 102000006947 Histones Human genes 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 101001076874 Homo sapiens C-Jun-amino-terminal kinase-interacting protein 3 Proteins 0.000 description 1
• 101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 1
• 101000828732 Homo sapiens Cornifin-A Proteins 0.000 description 1
• 101000944361 Homo sapiens Cyclin-dependent kinase inhibitor 1B Proteins 0.000 description 1
• 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
• 101001034314 Homo sapiens Lactadherin Proteins 0.000 description 1
• 101100077748 Homo sapiens MAP2K4 gene Proteins 0.000 description 1
• 101100457890 Homo sapiens MAP2K7 gene Proteins 0.000 description 1
• 101001018153 Homo sapiens Mitogen-activated protein kinase kinase kinase 1 Proteins 0.000 description 1
• 101000958409 Homo sapiens Mitogen-activated protein kinase kinase kinase 10 Proteins 0.000 description 1
• 101001055097 Homo sapiens Mitogen-activated protein kinase kinase kinase 6 Proteins 0.000 description 1
• 101001055085 Homo sapiens Mitogen-activated protein kinase kinase kinase 9 Proteins 0.000 description 1
• 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 description 1
• 101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 description 1
• 101900141355 Human T-cell leukemia virus 1 Protein Tax-1 Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 108010054031 Initiator Caspases Proteins 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• 102000013462 Interleukin-12 Human genes 0.000 description 1
• 108010065805 Interleukin-12 Proteins 0.000 description 1
• 102000003810 Interleukin-18 Human genes 0.000 description 1
• 108090000171 Interleukin-18 Proteins 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 102000004889 Interleukin-6 Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 101150026829 JUNB gene Proteins 0.000 description 1
• 101150021395 JUND gene Proteins 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 102100039648 Lactadherin Human genes 0.000 description 1
• 102000002297 Laminin Receptors Human genes 0.000 description 1
• 108010000851 Laminin Receptors Proteins 0.000 description 1
• 101710192602 Latent membrane protein 1 Proteins 0.000 description 1
• 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 102000002576 MAP Kinase Kinase 1 Human genes 0.000 description 1
• 108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 1
• 108010075656 MAP Kinase Kinase Kinase 2 Proteins 0.000 description 1
• 102000011853 MAP Kinase Kinase Kinase 5 Human genes 0.000 description 1
• 108010075639 MAP Kinase Kinase Kinase 5 Proteins 0.000 description 1
• 101150079589 MAP2K4 gene Proteins 0.000 description 1
• 229940126560 MAPK inhibitor Drugs 0.000 description 1
• 101710125418 Major capsid protein Proteins 0.000 description 1
• 206010064912 Malignant transformation Diseases 0.000 description 1
• 101150101215 Mapk8 gene Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
• 102100033058 Mitogen-activated protein kinase kinase kinase 2 Human genes 0.000 description 1
• 102100026889 Mitogen-activated protein kinase kinase kinase 6 Human genes 0.000 description 1
• 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
• 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 1
• 102100026909 Mitogen-activated protein kinase kinase kinase 9 Human genes 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 101100172512 Mus musculus Epha2 gene Proteins 0.000 description 1
• 101100457891 Mus musculus Map2k7 gene Proteins 0.000 description 1
• 101100099157 Mus musculus Rela gene Proteins 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 101800000597 N-terminal peptide Proteins 0.000 description 1
• 102400000108 N-terminal peptide Human genes 0.000 description 1
• 102100033102 NF-kappa-B inhibitor-like protein 1 Human genes 0.000 description 1
• 101710144707 NF-kappa-B inhibitor-like protein 1 Proteins 0.000 description 1
• 101000892448 Neisseria gonorrhoeae Type II restriction enzyme NgoMIV Proteins 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 101710141454 Nucleoprotein Proteins 0.000 description 1
• 108010047956 Nucleosomes Proteins 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 241000233805 Phoenix Species 0.000 description 1
• 101710114878 Phospholipase A-2-activating protein Proteins 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 description 1
• 101710193105 Plasmalemma vesicle-associated protein Proteins 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
• 101710083689 Probable capsid protein Proteins 0.000 description 1
• 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
• 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
• 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 102100036900 Radiation-inducible immediate-early gene IEX-1 Human genes 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• 101150001535 SRC gene Proteins 0.000 description 1
• 101710204410 Scaffold protein Proteins 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 230000020385 T cell costimulation Effects 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
• 102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 description 1
• 206010054094 Tumour necrosis Diseases 0.000 description 1
• 101710098624 Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
• 241000341910 Vesta Species 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 101710145727 Viral Fc-gamma receptor-like protein UL119 Proteins 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 229940098174 alkeran Drugs 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 230000003281 allosteric effect Effects 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000002583 anti-histone Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 230000009833 antibody interaction Effects 0.000 description 1
• 230000009831 antigen interaction Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 230000037429 base substitution Effects 0.000 description 1
• 108700000711 bcl-X Proteins 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 108020001778 catalytic domains Proteins 0.000 description 1
• 230000012820 cell cycle checkpoint Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 230000004640 cellular pathway Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• 238000003398 chloramphenicol acetyltransferase induction Methods 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 238000011490 co-immunoprecipitation assay Methods 0.000 description 1
• 238000012761 co-transfection Methods 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
• 238000010835 comparative analysis Methods 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 230000006552 constitutive activation Effects 0.000 description 1
• 238000011254 conventional chemotherapy Methods 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 238000002784 cytotoxicity assay Methods 0.000 description 1
• 231100000263 cytotoxicity test Toxicity 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
• 229950000950 daunorubicinol Drugs 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000002222 downregulating effect Effects 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 108700020302 erbB-2 Genes Proteins 0.000 description 1
• 201000007280 estrogen-receptor negative breast cancer Diseases 0.000 description 1
• 239000004060 excitotoxin Substances 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 102000018823 fas Receptor Human genes 0.000 description 1
• 108010052621 fas Receptor Proteins 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 238000007421 fluorometric assay Methods 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 229940076085 gold Drugs 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 238000012188 high-throughput screening assay Methods 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 230000005745 host immune response Effects 0.000 description 1
• 102000053440 human MAP3K1 Human genes 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 239000012642 immune effector Substances 0.000 description 1
• 102000027596 immune receptors Human genes 0.000 description 1
• 108091008915 immune receptors Proteins 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 239000012133 immunoprecipitate Substances 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000006623 intrinsic pathway Effects 0.000 description 1
• 230000005865 ionizing radiation Effects 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 238000005567 liquid scintillation counting Methods 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 230000036212 malign transformation Effects 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 210000003519 mature b lymphocyte Anatomy 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229960004452 methionine Drugs 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 231100000324 minimal toxicity Toxicity 0.000 description 1
• 230000004898 mitochondrial function Effects 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000008747 mitogenic response Effects 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 229930003658 monoterpene Natural products 0.000 description 1
• 235000002577 monoterpenes Nutrition 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 229940090009 myleran Drugs 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 239000006225 natural substrate Substances 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000009223 neuronal apoptosis Effects 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
• 210000001623 nucleosome Anatomy 0.000 description 1
• 230000006548 oncogenic transformation Effects 0.000 description 1
• 244000309459 oncolytic virus Species 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 230000011164 ossification Effects 0.000 description 1
• 238000007500 overflow downdraw method Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 238000004091 panning Methods 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229940063179 platinol Drugs 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 238000010379 pull-down assay Methods 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 125000003132 pyranosyl group Chemical group 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000014493 regulation of gene expression Effects 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000003307 reticuloendothelial effect Effects 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 238000004904 shortening Methods 0.000 description 1
• 125000005630 sialyl group Chemical group 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 108700026239 src Genes Proteins 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000004938 stress stimulation Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 101150047061 tag-72 gene Proteins 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 108091008743 testicular receptors 4 Proteins 0.000 description 1
• LZPBKINTWROMEA-UHFFFAOYSA-N tetracene-5,12-dione Chemical compound C1=CC=C2C=C3C(=O)C4=CC=CC=C4C(=O)C3=CC2=C1 LZPBKINTWROMEA-UHFFFAOYSA-N 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 229940124788 therapeutic inhibitor Drugs 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 238000000015 thermotherapy Methods 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 238000006276 transfer reaction Methods 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 230000005909 tumor killing Effects 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 238000001086 yeast two-hybrid system Methods 0.000 description 1